Tagged with ase

Turkey Ercin Kugu, CSL Behring’s general manager for Turkey and Israel, highlights the rare disease company’s footprint in Turkey, explains the different regulatory framework in the country for plasma products, and provides insights on the process of establishing Big Pharma affiliates in Turkey from zero after doing so for both Shire…

USA The National Organization for Rare Disorders (NORD) is set to host its annual Rare Diseases and Orphan Products Breakthrough Summit on October 18-19th. Ahead of the Summit, the Chair of NORD’s Board of Directors Kay Holcombe explains its significance for cross-stakeholder interaction and learning and why we are entering “a…

Saudi Arabia Kamel Ghammachi and Karim Smaira are the co-founders of Genpharm, an entrepreneurial success story that now provides market access and marketing solutions for rare disease products across the MENA region. They discuss the impact of COVID-19 on their business; the evolving dynamics of the Saudi pharma market; and the crucial…

Turkey Few Turkish companies are experiencing such a transformational moment as GEN. Just in 2021, the Ankara-based organization made its public debut at the Istanbul Stock Exchange and signed an exclusive collaboration agreement with a Dutch biotech company for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative…

Denmark Industry veteran Patrik Forsell oversees Takeda’s operations in Denmark. Here, Forsell talks through how sizeable shifts in the company’s global portfolio and focus over the past four years have played out at the Danish level, the increasingly challenging market access situation for rare disease treatments in the country, and how…

Saudi Arabia Rodrigo Rodriguez, general manager for Takeda’s Middle East cluster, discusses the company’s ambitions in the collective Saudi pharma market, which is expected to reach a size of USD 10 billion by 2025, the need for tailor-made programs for different countries in the Middle East, and how clinical trials and registry…

Global Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing countries with lysomal storage disorders who would otherwise not have access. Sibold outlines the persistent obstacles facing people with rare…

Singapore Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world. “It’s important not to overlook the strengths of this system and just how strong healthcare delivery, affordability and access is…

Singapore Industry veteran Marine Queniart-Stojanovic outlines the significance of the Thailand-Malaysia-Singapore country grouping to Sanofi’s APAC operations; how the company’s global rationalisation and prioritisation push has been reflected at the country level; and why inter-stakeholder collaboration will be crucial to developing patient-centric solutions in a post-pandemic world.   I always come…

Turkey Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how the organization has seized on Takeda’s revamped portfolio, focusing on rare diseases, haematology, immunology, gastroenterology, and oncology, to move up…

Singapore EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment destination.   Value-Based healthcare in this part of the world will be implemented in different ways. It will come less…

Singapore Dr Varun Sethi outlines some of the most important trends in ASEAN healthcare today and how DKSH, as a historic business services provider, is adapting its offering to meet them.   Singapore has always been considered the bellwether of driving innovation in the region, which remains the case. In terms…